The 5-Second Trick For DO-264
The 5-Second Trick For DO-264
Blog Article
quinupristin/dalfopristin increases levels of erythromycin lactobionate by reducing metabolism. Contraindicated. Hazard of extended QTc interval.
This drugs may well lead to diarrhea, and sometimes it may be serious. It may well arise 2 months or more When you cease receiving this medication.
quinupristin/dalfopristin will increase the level or result of finasteride by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unfamiliar.
quinupristin/dalfopristin will boost the level or influence of digoxin by altering intestinal flora. Applies only to oral sort of both brokers. Use Warning/Observe.
quinupristin/dalfopristin will boost the stage or effect of trazodone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
quinupristin/dalfopristin will increase the degree or influence of mavorixafor by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
quinupristin/dalfopristin will raise the degree or effect of nifedipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Mysterious.
quinupristin/dalfopristin will improve the degree or effect of dasatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
quinupristin/dalfopristin will boost the RO5256390 amount or influence of erythromycin base by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug.
Minimal (one)quinupristin/dalfopristin will decrease the level or result of pantothenic acid by altering intestinal flora. Applies only to oral type of both equally brokers. Minor/Significance Unidentified.
quinupristin/dalfopristin will enhance the amount or impact of palovarotene by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
Check Closely (one)quinupristin/dalfopristin will reduce the level or effect of dienogest/estradiol valerate by altering intestinal flora.
Although certain medicines really should not be applied jointly in any way, in other situations two different medicines may very well be applied jointly whether or not an interaction could arise. In these circumstances, your physician should want to change the dose, or other safeguards might be necessary.
quinupristin/dalfopristin will enhance the stage or outcome of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Monitor for adverse results if lefamulin is coadministered with reasonable CYP3A inhibitors.